2023: Upcoming Drug Pricing Developments to Look Out For

With the passage of the US Democrats’ Inflation Reduction Act and increased scrutiny over the practices of pharmacy benefit managers (PBMs), 2023 is set to be a year defined by drug pricing for pharma. In a new Law360 article, learn about 5 key upcoming issues related to drug prices to keep an eye on in the upcoming year. One key issue are Medicare price negotiations.

According to , “Biden’s October executive order, intended as a supplement to the law, directs HHS’ Center for Medicare and Medicaid Innovation to consider and test new payment and delivery models to lower drug costs, including value-based care payment models. The Medicare price negotiation provisions in the IRA have garnered the most attention. Manufacturers and other stakeholders have raised concerns that the law will curb innovation and signaled their intent to challenge the provision.”

To read more, click here.

(Source: Law360, December 19^th, 2022)